RxDoctor Payments Data

Ehab Morcos, MD

Interventional Cardiology · Greensburg, PANPI 1528028842

Payments from drug & device makers

$6,270in general payments, 2019–2025

Across 163 payments — averaging $38.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$2K
  • Boehringer Ingelheim$595
  • Boston Scientific$589
  • Amgen$431
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$392
  • Shockwave Medical, Inc$389
  • plus $2K from 12 others

What the payments were for

  • Travel & lodging$1,37922%
  • Food & beverage$4,89178%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,270 in reported general payments places this provider in the 40th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$112,844
Medicare patients
429
Services billed
3,005

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban203$177,290
EntrestoSacubitril/Valsartan36$32,124
XareltoRivaroxaban22$27,677
JardianceEmpagliflozin29$22,387
Metoprolol Succinate319$5,394
Telmisartan105$3,488
Atorvastatin Calcium249$3,180
Warfarin Sodium229$3,168
Ezetimibe101$2,743
Rosuvastatin Calcium69$2,724
ClopidogrelClopidogrel Bisulfate171$2,388
Diltiazem 24hr Er (Cd)Diltiazem Hcl100$2,242
Valsartan78$2,097
Amiodarone Hcl85$1,914
Isosorbide Mononitrate ErIsosorbide Mononitrate125$1,796

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$148$32,12436 claims
Boehringer IngelheimJardiance$595$22,38729 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Greensburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →